Updates

February 21, 2020February 21, 2020
Xpovio May Soon Be Available in Israel and Palestinian Authority, Karyopharm Says

Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive distribution agreement ... Read more
February 19, 2020February 19, 2020
Darzalex Combo Leads to Durable Responses in Patients With Advanced Multiple Myeloma, Follow-up Data Show

Janssen‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone continues to lead to strong and durable responses, and prolong the time until disease ... Read more
February 17, 2020February 17, 2020
Kleo’s KP1237 Therapy Soon Will Enter Clinical Testing, Following FDA’s Grant of New Drug Status

KP1237, an experimental therapy by Kleo Pharmaceutical that harnesses the body’s natural antibodies to fight cancers, will soon enter clinical testing for multiple myeloma, ... Read more
February 12, 2020February 12, 2020
Phase 1/2 Trial of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma to Open Soon

A clinical trial is soon to begin testing Precision BioSciences‘s new CAR T-cell therapy candidate, PBCAR269A, in people with relapsed or refractory multiple myeloma. The Phase 1/2a ... Read more
February 11, 2020February 14, 2020
FDA Asked to Approve Darzalex Triple Combo for Relapsed or Refractory Multiple Myeloma

Janssen has asked the U.S. Food and Drug Administration (FDA) to allow Darzalex (daratumumab) to also be used in combination with Kyprolis (carfilzomib) and dexamethasone to treat people with ... Read more

News

Antibiotics Prevent Fevers, Death in Newly Diagnosed Myeloma Patients, Study Says
February 10, 2020February 10, 2020
Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death ...
News

Advancing Novel Cell Therapy for Myeloma and Multiple Cancers Goal of New Partnership
February 7, 2020February 7, 2020
A recent partnership between Indapta Therapeutics and Lonza is advancing the development of an off-the-shelf ...
News

EMA Reviewing Belantamab Mafodotin for Heavily Pretreated Multiple Myeloma
February 5, 2020
The European Medicines Agency has agreed to review the application of GlaxoSmithKline‘s belantamab mafodotin for the ...
News

Takeda, Snow Myeloma App ‘Being Patient’ Wins Pharma Choice Award
February 3, 2020February 3, 2020
Takeda and Snow Companies won one of the top prizes in PM360’s annual Pharma ...
News

Researchers Provide Highlights on Study into Benefits of Reolysin, Kyprolis Combo in Multiple Myeloma
January 31, 2020January 31, 2020
Researchers are continuing to study how the combination of Oncolytics Biotech‘s virus-based anti-cancer therapy ...
News

Allogene, SpringWorks Collaborate to Test ALLO-715, Nirogacestat Combo for RRMM
January 29, 2020January 29, 2020
Allogene Therapeutics and SpringWorks Therapeutics have launched a clinical trial collaboration to conduct a ...

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
January 27, 2020January 27, 2020
Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will ...
FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma
January 24, 2020January 24, 2020
The U.S. Food and Drug Administration (FDA) has granted priority review status to GlaxoSmithKline‘s application seeking the ...
Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients
January 21, 2020January 22, 2020
NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients
January 20, 2020January 20, 2020
IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma
January 17, 2020January 17, 2020
First Mainland China Patient Dosed in Pivotal Phase 2 Trial Testing MOR202 in Multiple Myeloma
January 15, 2020January 15, 2020

Pivotal DREAMM-2 Trial Supports Belantamab Mafodotin’s Use for Heavily-treated Multiple Myeloma
January 13, 2020January 13, 2020
Treatment with belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, resulted in clinically meaningful responses in ...
Myeloma Patients in Phase 1 Trial Show High Response Rates with REGN5458 Treatment
January 10, 2020January 10, 2020
PNK-007 Treatment After Stem Cell Transplant Leads to Good Response Rates in Multiple Myeloma Patients, Early Trial Data Show
January 8, 2020January 8, 2020
Analysis Group Announces Collaboration to Improve Blood Disease Research and Treatment in China
January 6, 2020January 6, 2020

Switching Chemo Types in Initial Combo May Help Myeloma Patients with Poor Response, Study Says
December 20, 2019December 20, 2019
For people with multiple myeloma who don’t respond well to an initial type of ...
Top 10 Multiple Myeloma Stories of 2019
December 19, 2019January 3, 2020
CHMP Recommends EU Approval of Darzalex Combo as First-line Treatment for Transplant-eligible Myeloma Patients
December 16, 2019December 18, 2019

News

MGUS Patients Have More Frequent Hospital Visits Prior to Diagnosis than Healthy Controls, Research Shows
December 13, 2019December 13, 2019
People with monoclonal gammopathy of undetermined significance (MGUS), a rarely diagnosed condition that can ...
News

Advanced Multiple Myeloma Patients Responding to Janssen’s CAR T-cell Therapy, Trial Data Show
December 10, 2019December 16, 2019
Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528 (JNJ-68284528), safely led to ...
News

Kyprolis Combo Followed by Stem Cell Transplant is Effective for Most Smoldering Multiple Myeloma, Data Show
December 9, 2019December 9, 2019
A combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone, given before and immediately after ...
News

Ninlaro Triple Combo Delays Progression of High-Risk Smoldering Multiple Myeloma, Trial Suggests
December 6, 2019December 6, 2019
Early treatment with a triple combination therapy containing Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone in ...
News

Venclexta-Darzalex Combos Show Strong Response Rates in Multiple Myeloma Trial, Early Data Show
December 4, 2019December 12, 2019
Adding the antibody Darzalex (daratumumab) to Venclexta (venetoclax), a lymphoma and leukemia treatment, is a ...
News

Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show
December 3, 2019December 4, 2019
Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma ...
News

Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces
December 2, 2019December 2, 2019
Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients ...
News

AbbVie Obtains Global Rights Option for HPN217, Phase 1/2 Trial in Multiple Myeloma Planned
November 27, 2019November 27, 2019
Harpoon Therapeutics has granted AbbVie an option for exclusive worldwide rights to HPN217, a treatment ...
News

BiCNU Generic for Multiple Myeloma, Other Cancers Launched in US
November 25, 2019November 25, 2019
Carmustine for Injection, a generic version of the chemotherapy BiCNU, has been launched in ...

October 30, 2017October 30, 2017

Pomalyst Is More Cost-effective Than Darzalex or Kyprolis for Heavily Treated Myeloma Patients, Study Reports

News

A combination of Pomalyst (pomalidomide) and low-dose dexamethasone is cheaper than either Darzalex (daratumumab) or Kyprolis (carfilzomib) alone as a treatment for relapsed or refractory multiple myeloma (RRMM), a study shows. The research, published in Clinical Therapeutics, is titled “Cost-effectiveness of Pomalidomide, Carfilzomib, ... Read more

Subscribe to our mailing list

Pin It on Pinterest